

Toxic Shock Syndrome

<http://www.emedicine.com/med/topic2292.htm>

Last Updated: October 5, 2006

Synonyms and related keywords: toxic shock syndrome, TSS, flesh-eating disease, toxic shock, septic shock, *Staphylococcus aureus*, *S aureus*, group A *Streptococcus*, GAS, *Streptococcus pyogenes*, *S pyogenes*

AUTHOR INFORMATION

Section 1 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Author: **Sat Sharma, MD, FRCPC, FACP, FCCP, DABSM**, Program Director, Associate Professor, Department of Internal Medicine, Divisions of Pulmonary and Critical Care Medicine, University of Manitoba; Site Director of Respiratory Medicine, [St Boniface General Hospital](#)

Coauthor(s): **Godfrey Harding, MD, FRCPC**, Program Director of Medical Microbiology, Professor, Department of Medicine, Section of Infectious Diseases and Microbiology, St Boniface Hospital, University of Manitoba, Canada; **Ken Dolynchuk, MD, PhD, FRCSC**, Associate Professor, Departments of Surgery, Biochemistry and Molecular Biology, University of Manitoba, Canada

Sat Sharma, MD, FRCPC, FACP, FCCP, DABSM, is a member of the following medical societies: [American Academy of Sleep Medicine](#), [American College of Chest Physicians](#), [American College of Physicians-American Society of Internal Medicine](#), [American Thoracic Society](#), [Canadian Medical Association](#), [Royal College of Physicians and Surgeons of Canada](#), [Royal Society of Medicine](#), [Society of Critical Care Medicine](#), and [World Medical Association](#)

Editor(s): **Cory Franklin, MD**, Professor, Department of Medicine, Rosalind Franklin University of Medicine and Science; Director, Division of Critical Care Medicine, Cook County Hospital; **Francisco Talavera, PharmD, PhD**, Senior Pharmacy Editor, eMedicine; **Richard B Brown, MD, FACP**, Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine; **Eleftherios Mylonakis, MD, PhD**, Assistant Professor of Medicine, Harvard Medical School, Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital; and **Burke A Cunha, MD, MACP**, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital

[Disclosure](#)

INTRODUCTION

Section 2 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Background: Toxic shock syndrome (TSS) is a toxin-mediated multisystem disease precipitated by infection with either *Staphylococcus aureus* or group A *Streptococcus* (GAS), also called

Streptococcus pyogenes. The clinical syndrome is characterized by a rapid onset of high fever, hypotension, diffuse rash (petechial or maculopapular), severe myalgia, vomiting, diarrhea, headache, and nonfocal neurologic abnormalities. Mortality is high.

TSS was first described in children in 1978 (Todd, 1978). Subsequent reports identified an association with tampon use by menstruating women (Shands, 1980; Davis, 1980). In the 1980s, Cone initially reported and Stevens subsequently characterized GAS as a pathogen responsible for invasive soft tissue infection ushered by toxic shock–like syndrome (Cone, 1987; Stevens, 1989). The streptococcal TSS is identical to staphylococcal TSS (STSS), except that the blood cultures usually are positive for staphylococci in STSS. Toxin-producing strains of *S aureus* infect or colonize people who have risk factors for the development of the syndrome. Most cases are related to the staphylococcal toxin, now called TSS toxin-1 (TSST-1).

GAS is an aerobic gram-positive organism that forms chains and is an important cause of soft tissue infections. Severe, invasive GAS infections can cause necrotizing fasciitis and spontaneous gangrenous myositis. An increasing number of severe GAS infections associated with shock and organ failure have been reported. These infections are termed streptococcal TSS.

Pathophysiology:

Bacteriology

M protein is an important virulent determinant of GAS; strains lacking M protein are less virulent. M protein is a filamentous protein anchored to the cell membrane, which has antiphagocyte properties. M types 1, 3, 12, and 28 are the most common isolates found in patients with shock and multiorgan failure; furthermore, 3 distinct streptococcal pyrogenic exotoxins (ie, A, B, C) also have been identified. These toxins induce cytotoxicity and pyrogenicity and enhance the lethal effects of endotoxins. Recently, the streptococcal super antigen, a pyrogenic exotoxin, has been isolated from an M-3 strain.

Mechanism of shock and tissue destruction

Colonization or infection with certain strains of *S aureus* and GAS is followed by the production of 1 or more toxins. These toxins are absorbed systemically and produce the systemic manifestations of TSS in people who lack a protective antitoxin antibody. Possible mediators of the effects of the toxins are cytokines, such as interleukin 1 (IL-1) and tumor necrosis factor (TNF). Pyrogenic exotoxins induce human mononuclear cells to synthesize TNF-alpha, IL-1-beta, and interleukin 6 (IL-6).

TSS likely relates to the ability of pyrogenic exotoxins of GAS and enterotoxins of *S aureus* to act as super antigens. These exotoxins and several staphylococcal toxins (eg, TSST-1) can stimulate T-cell responses through their ability to bind to both the class II major histocompatibility complex of antigen-presenting cells and T-cell receptors. These toxins bind the beta chain variable region (V-beta) elements on T-cell receptors and simultaneously bind to the class II major histocompatibility antigen-processing cells. This mechanism bypasses the classical antigen-processing procedures and results in excessive T-cell proliferation. The conventional antigens activate only about 0.01% to 0.1% of the T-cell population, whereas, the superantigens set in motion 5 to 30% of the entire T-cell population. The net effect is massive production of cytokines that are capable of mediating shock and tissue injury. Other exotoxins (eg, streptolysin O, exotoxin B) and cell wall components also are important inducers of TNF-alpha and IL-1 and IL-6. Both TNF-alpha and IL-1-beta play a role in the pathogenesis of TSS.

Frequency:

- **In the US:** Estimates from population-based studies have documented an incidence of invasive GAS infection of 1.5-5.2 cases per 100,000 people annually (Davies, 1996). Approximately 8-14% of these patients also will develop TSS (Eriksson, 1998). A history of recent varicella infection markedly increases the risk of infection with GAS to 62.7 cases per 100,000 people per year. Severe soft tissue infections, including necrotizing fasciitis, myositis, or cellulitis, were present in approximately half of the patients.

STSS is much more common, although data on prevalence do not exist. In the United States, from 1979-1996, 5296 cases of STSS were reported. The number of cases of menstrual STSS is estimated at 1 per 100,000. The incidence of nonmenstrual STSS now exceeds menstrual STSS after the hyperabsorbable tampons were removed from the market.

Mortality/Morbidity: Mortality rates for streptococcal TSS are 30-70% (Stevens, 1992; Demers, 1993). Morbidity also is high; in one series, 13 of 20 patients underwent major surgical procedures, such as fasciotomy, surgical debridement, laparotomy, amputation, or hysterectomy (Stevens, 1989; Stevens, 1992).

The case fatality rates for menstrual-related STSS have declined from 5.5% in 1980 to 1.8% in 1996.

Race: TSS has occurred in all races, although most cases have been reported from North America and Europe.

Sex: STSS most commonly occurs in women, usually those who are using tampons.

Age: Some studies have shown no predilection for any particular age for either the streptococcal TSS or STSS. However, other studies have reported STSS to be more common in older individuals with underlying medical problems. In a Canadian survey, STSS accounted for 6% of cases in individuals younger than 10 years compared with 21% in people older than 60 years (Davies, 1996). Furthermore, menstruation-associated STSS occurred in younger women who were using tampons.

CLINICAL

Section 3 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

History: The possibility of toxic shock should be considered in any individual who presents with sudden onset of fever, rash, hypotension, renal or respiratory failure, and changes in mental status.

- STSS most commonly occurs in women, usually those who are using tampons, TSS develops within 5 days after the onset of menstruation. The other clinical settings where STSS has been reported include the following:
 - Surgical wound infections
 - Postpartum infections
 - Focal cutaneous and subcutaneous lesions
 - Deep abscesses
 - Empyema
 - Peritonsillar abscess
 - Sinusitis
 - Osteomyelitis

- Soft tissue infections from GAS include necrotizing fasciitis, myositis, or cellulitis. The most common initial symptom of patients with streptococcal TSS is diffuse or localized pain that is abrupt and severe. Other manifestations include the following:
 - Influenzalike syndrome
 - Fever
 - Confusion
 - Signs of soft tissue infection
- Approximately 20% of patients with STSS have an influenzalike syndrome characterized by the following:
 - Fever
 - Chills
 - Myalgia
 - Nausea
 - Vomiting
 - Diarrhea
- The other reported types of infection are pneumonia, unidentified bacteremia, surgical site infection, septic arthritis, thrombophlebitis, meningitis, pelvic infection, and endophthalmitis.
- Common presenting symptoms and frequency of STSS are as follows (Stevens, 1989):
 - Pain (44-85%)
 - Vomiting (25-26%)
 - Nausea (20%)
 - Diarrhea (14-30%)
 - Influenzalike symptoms (14-20%)
 - Headache (10%)
 - Dyspnea (8%)
- The following risk factors have been reported to be associated with STSS:
 - Patients with HIV, diabetes, cancer, ethanol abuse, and other chronic diseases
 - Patients with a recent history of varicella infection (chicken pox)
 - Patients who used nonsteroidal anti-inflammatory drugs (NSAIDs)

Physical: Fever is the most common presenting sign, although patients in shock may present with hypothermia. Shock is apparent at the time of hospitalization or within 4-8 hours for all patients. Patients become severely hypotensive and do not respond to intravenous fluid administration. Renal dysfunction progresses or persists in all patients, precedes shock in many patients, and is apparent early. Acute respiratory distress syndrome occurs in 55% of patients and requires mechanical ventilation.

A thorough search for possible sites of streptococcal and staphylococcal infection is a must. The surgical wounds should be carefully examined even if no signs of infection are apparent. Vaginal examination and removal of tampon or other foreign body should be de rigueur.

- Confusion is present in 55% of patients, and coma or agitation may occur.
- Nearly 50% of patients are normotensive on presentation but become hypotensive within 4 hours.
- Approximately 80% of patients have clinical signs of soft tissue infection (eg, localized swelling, erythema), which usually progresses to necrotizing fasciitis or myositis.
- Approximately 20% of patients have various clinical presentations, including the following:
 - Endophthalmitis
 - Myositis
 - Perihepatitis
 - Peritonitis
 - Myocarditis
- Diffuse scarlatinalike erythema occurs in 10% of patients.
- Skin manifestations of streptococcal infection include the following:
 - Bullae
 - Scarlet fever–like rash
 - Petechiae or maculopapular rashes
 - Desquamation
- The possibility of STSS should be entertained in any patient who presents with a sudden onset of fever, rash, hypotension, and systemic evidence of toxicity. Five categories of clinical features are needed for the diagnosis, as follows (Centers for Disease Control and Prevention, 1990):
 - Fever
 - Rash - A diffuse macular erythroderma
 - Desquamation - Occurs 1-2 weeks after onset of illness, involving palms and soles
 - Hypotension (systolic blood pressure <90 mm Hg, orthostatic drop in diastolic blood pressure <15 mm Hg, orthostatic syncope, and dizziness)
 - Evidence of multisystem involvement in 3 or more of the following systems:
 - Gastrointestinal - Vomiting or diarrhea at the onset of illness
 - Muscular - Severe myalgia or creatine kinase (CK) elevation (>2 times normal upper limit)
 - Mucous membrane - Vaginal, oropharyngeal, or conjunctival erythema
 - Renal - BUN or serum creatinine greater than 2 times the upper limit of normal
 - Hepatic - Bilirubin or transaminases greater than 2 times the upper limit of normal
 - Hematological - Platelets less than 100,000
 - Central nervous system - Disorientation or alteration in consciousness without focal signs
- Common presenting symptoms and frequency of STTS are (Stevens, 1989) as follows:

- Tachycardia (80%)
- Fever (70-81%)
- Hypotension (44-65%)
- Confusion (55%)
- Localized erythema (44-65%)
- Localized swelling and erythema (30-75%)
- Scarletiform rash (0-4%)
- Case definition of streptococcal TSS (Working group definition, JAMA 1993)
 - Isolation of GAS (*S pyogenes*) from a normally sterile site, eg, blood, cerebrospinal fluid, pleural fluid (definite case), or nonsterile site (probable case) and hypotension (systolic pressure ≤ 90 mm Hg in adults or less than fifth percentile for children)
 - Multiorgan involvement, as evidenced by at least 2 of the following:
 - Renal impairment - Creatinine level more than $177 \mu\text{mol/L}$ for adults or twice upper normal limit for age or more than twice the baseline level for patients with renal disease
 - Coagulopathy - Platelet count less than $100 \times 10^6/\text{L}$ or disseminated intravascular coagulation
 - Liver involvement - Alanine aminotransferase, aspartate aminotransferase, or total bilirubin level more than twice normal limit for age or more than twice baseline in patients with chronic liver disease
 - Pulmonary involvement - Adult respiratory distress syndrome or evidence of diffuse capillary leak syndrome
 - Generalized erythematous macular rash
 - Soft tissue necrosis (necrotizing infection, necrotizing myositis, or gangrene)

Causes:

- Acquisition of infection
 - Risk factors for the development of STSS are tampon use, vaginal colonization with toxin-producing *S aureus*, and lack of serum antibody to the staphylococcal toxin. STSS also has occurred following use of nasal tampons for procedures of the ears, nose, and throat.
 - The portal of entry for streptococci is unknown in almost one half of the cases. Procedures such as suction lipectomy, hysterectomy, vaginal delivery, and bone pinning have been identified as the portal of entry in many cases. Most commonly, infection begins at a site of minor local trauma, which may be nonpenetrating. Viral infections, such as varicella and influenza, also have provided a portal of entry.

[Cellulitis](#)

[Clostridial Gas Gangrene](#)

[Erythema Multiforme \(Stevens-Johnson Syndrome\)](#)

[Fever of Unknown Origin](#)
[Gas Gangrene](#)
[Infectious Mononucleosis](#)
[Infective Endocarditis](#)
[Kawasaki Disease](#)
[Listeria Monocytogenes](#)
[Meningococcal Infections](#)
[Meningococemia](#)
[Pharyngitis, Bacterial](#)
[Pneumonia, Bacterial](#)
[Sepsis, Bacterial](#)
[Septic Shock](#)
[Shock, Distributive](#)
[Shock, Hemorrhagic](#)
[Staphylococcal Infections](#)
[Streptococcus Group A Infections](#)

Other Problems to be Considered:

The differential diagnosis includes the following:

Heat stroke

Leptospirosis

Rubeola

Rocky Mountain spotted fever (RMSF): Severe headache and rash are present in most patients with this disorder. The rash is petechial in patients with RMSF, whereas it is diffusely erythematous in patients with TSS.

Rash-associated viral infections

Meningococemia

Streptococcal or staphylococcal scarlet fever

Drug reactions

Kawasaki syndrome

Toxic epidermal necrolysis

Gram-negative sepsis: This condition may mimic TSS but is uncommon in healthy patients outside the hospital setting.

Typhoid fever: This is a food-borne illness that also should be distinguished from TSS.

WORKUP

Section 5 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Lab Studies:

- CBC count with differential
 - Leukocytosis with a polymorphonuclear shift to the left
 - Mild leukocytosis with significant immature neutrophils on peripheral smear
- Urinalysis
 - Myoglobinuria and hemoglobinuria present
 - Sterile pyuria

- Prolonged prothrombin and activated partial thromboplastin times
- Serum biochemistry
 - Serum creatinine - Frequently elevated and precedes the development of hypotension in 50% of cases
 - Hypoglycemia
 - Low serum protein and albumin concentrations
 - Elevated blood urea nitrogen
 - Elevated transaminases
 - Elevated bilirubin and creatine phosphokinase levels
 - In myositis or necrotizing fasciitis, elevated serum creatinine kinase concentration
- Blood cultures
 - Blood cultures positive for bacteria - Present in approximately 60% of the cases of disease associated with GAS
 - Compared with STSS, blood cultures usually positive for staphylococci
- Gram stain and cultures
 - *S aureus* - Identified easily by Gram stain and culture from a well-defined focus of infection (eg, abscess, wound infection)
 - In cases associated with menstruation, as many as 90% of patients demonstrate the organism in cultures from the cervix or vagina, in the absence of clinical infection.
 - *S aureus* bacteremia - Uncommon in patients with TSS
- Common laboratory abnormalities in patients with streptococcal TSS (Stevens, 1989):
 - Hypoalbuminemia (85%)
 - Hypocalcemia (79%)
 - Elevated liver transaminase levels (63%)
 - Prolonged prothrombin time and/or activated partial thromboplastin time (60-71%)
 - Elevated creatinine level (40-89%)

Imaging Studies:

- Chest radiographs: Patients who develop multiorgan dysfunction will have bilateral airspace infiltrates consistent with acute respiratory distress syndrome.

Staging:

Case definition of streptococcal TSS

- Isolation of GAS
 1. From a sterile site
 2. From a nonsterile body site
- Clinical signs of severity

1. Hypotension
 2. Clinical and laboratory abnormalities (requires 2 or more of the following): (1) renal impairment; (2) coagulopathy; (3) liver abnormalities; (4) acute respiratory distress syndrome; (5) extensive tissue necrosis, ie, necrotizing fasciitis; and (6) erythematous rash.
- Definite case - Isolation of GAS from a sterile site and hypotension and 2 or more of the clinical and laboratory abnormalities
 - Probable case - Isolation of GAS from a nonsterile body site and hypotension and 2 or more of the clinical and laboratory abnormalities

TREATMENT

Section 6 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Medical Care: TSS has a rapid, dramatic, and fulminant onset. Quick recognition of the syndrome is important for enabling appropriate and prompt treatment. *S pyogenes* continues to be susceptible to beta-lactam antibiotics. Although very effective in treating pharyngitis and other superficial infections, aggressive GAS infections do not respond well to penicillin and continue to be associated with high mortality rates and extensive morbidity.

The principles in the management of septic shock in general must be instituted as soon as possible (see [Septic Shock](#)). These include the following components:

1. Early recognition
 2. Early and adequate antibiotic therapy
 3. Source control
 4. Early hemodynamic resuscitation and continued support
 5. Corticosteroids (refractory vasopressor-dependent shock)
 6. Drotrecogin alpha (Severely ill if APACHE II > 25)
 7. Tight glycemic control
 8. Proper ventilator management with low tidal volume in patients with acute respiratory distress syndrome (ARDS)
- In experimental models of *S pyogenes* infection, penicillin proved to be inferior to clindamycin. The physiologic state of the organism attributed to the inoculum effects is suggested as the mechanism of failure.
 - Penicillin and other beta-lactam antibiotics are most efficacious against rapidly growing bacteria; therefore, these antibiotics have the greatest efficacy when organisms are growing rapidly during the early stages of infection or in mild infections. When higher concentrations of GAS accumulate (eg, deep-seeded infections), the effectiveness of beta-lactam antibiotics decreases because the bacterial growth slows (stationary phase).
 - Penicillin mediates its antibacterial action against GAS by interacting with penicillin-binding proteins (PBPs). Experimentally, the binding of penicillin has been shown to decrease in stationary cells, related to cells in the logarithmic growth phase; thus, the loss of certain PBPs during the stationary growth phase may be secondary to the inoculum effect and may account for penicillin failure.
 - Clindamycin
 - This drug has multiple effects against GAS infection.

- The efficacy of clindamycin is not affected by inoculum size or growth stage; furthermore, this agent is a potent suppressor of bacterial toxin synthesis.
- Clindamycin facilitates phagocytosis of *S pyogenes* by inhibiting M protein synthesis.
- Clindamycin suppresses synthesis of PBPs, which also are enzymes involved in cell wall synthesis.
- Clindamycin has a longer postantibiotic effect than penicillin.
- Clindamycin causes suppression of lipopolysaccharide-induced monocyte synthesis of TNF.
- Recommended antibiotic therapy
 - For patients with GAS infection, the administration of clindamycin (900 mg IV q8h) is recommended. Other clinicians recommend combined therapy, in which penicillin G (4 million U IV q4h) is combined with clindamycin.
 - Because differentiating between STSS and streptococcal TSS on clinical grounds alone is difficult, intravenous penicillin also should be administered in addition to a beta-lactamase resistant antibiotic until a bacteriologic diagnosis is confirmed by culture. Alternatively, a first-generation cephalosporin or vancomycin can be used.
- Staphylococcal toxic shock syndrome
 - Large doses of a beta-lactamase-resistant, antistaphylococcal, antimicrobial agent should be administered intravenously to patients with staphylococcal infections. The usually prescribed antibiotics are nafcillin, oxacillin, and first generation cephalosporin. Nafcillin or oxacillin (2 g q4h) is generally recommended. Vancomycin can be used in penicillin-allergic patients.
 - These agents have been known to increase TSST-1 in culture possibly by cell lysis. Therefore, clindamycin may be used in combination for the first few days to reduce synthesis of TSST-1.
 - The antibiotic treatment is continued for 10 to 14 days in absence of a complication.
- Intravenous fluids
 - TSS causes intractable hypotension and diffuse capillary leak; therefore, massive amounts of intravenous fluids (10-15 L/d) often are necessary. Patients in shock may require central venous monitoring or right heart catheterization to guide fluid management.
 - The patient's blood pressure may improve with administration of fluids alone; otherwise, vasopressors (eg, dopamine) or even more potent vasoconstrictors (eg, norepinephrine) are required. Norepinephrine with or without dobutamine may be more effective than high-dose dopamine or epinephrine to preserve splanchnic perfusion.
 - Patients with TSS will require supportive measures, including intubation and mechanical ventilation, dialysis in patients who have developed renal failure, and adequate nutritional support.
- Other treatment measures
 - Intravenous immunoglobulin: Several anecdotal reports, 1 large series of 21 patients and a case control study, reported lower mortality rates for patients with STSS treated with intravenous immunoglobulins (Demers, 1993; Stevens, 1998; Kaul, 1999). Intravenous immunoglobulins also have been reported to be beneficial in

severe cases of STSS. The recommended initial dosage is 2 g/kg, followed by 0.4 g/kg for as long as 5 days.

The mechanism responsible for the efficacy of gamma-globulin therapy may be neutralization of the circulating toxins, inhibition of TNF-alpha production via nonspecific inhibition of monocyte or T-cell activation, or inhibition of other streptococcal virulence factors. The contraindications include a history of anaphylaxis from immune globulin in past, immunoglobulin A (IgA) deficiency, and circulating anti-IgA antibodies.

A recent case series described 7 patients with severe soft tissue infection caused by GAS and toxic shock syndrome. All were treated with effective antimicrobials and high-dose intravenous immune serum globulin (IVIG). Surgery was either not performed or only limited exploration was carried out. Six of the patients had toxic shock syndrome. The study suggests that the use of a medical regimen including IVIG in patients with severe GAS soft tissue infections may allow a minimally invasive approach. This can limit the need to perform immediate wide debridements and amputations in unstable patients (Norrby-Teglund, 2005).

Another prospective, randomized, controlled study included patients with severe sepsis and septic shock of intra-abdominal origin admitted to the ICU. Polyvalent IgM-enriched immunoglobulin (Ig) (Pentaglobin; IVIG group) at a dosage of 7 mL/kg/day for 5 days or an equal amount of 5% human albumin (control group) was randomized. Fifty-six patients were enrolled. The overall mortality rate was 37.5%. In the intent-to-treat analysis, the mortality rate was reduced from 48.1% in patients treated with antibiotic plus albumin to 27.5% for patients with antibiotic plus IVIG. IVIG administration in combination with adequate antibiotics improved the survival of surgical ICU patients with intra-abdominal sepsis (Rodriguez, 2005).

- Hyperbaric oxygen has been used anecdotally in few patients, but whether this treatment is useful is not clear.
- High-dose corticosteroid therapy has not been shown to be beneficial; if adrenal suppression is suspected, empirical dexamethasone (4 mg IV qid) may be initiated until results of the adrenocorticotrophic hormone (ACTH) stimulation test become available.
- In recent years, research is continuing to develop either monoclonal antibodies against TSST-1 or other peptides to block the ability of bacterial toxins to activate T cells, therefore blocking the toxicity cascade. Most of this research presently is focused on in vitro and animal models of toxic shock.

Surgical Care: Prompt, aggressive exploration and debridement of patients thought to have deep-seeded pyogenic infection constitutes a surgical emergency. Surgical exploration through a small incision with visualization of the muscle and fascia may provide an early and definitive diagnosis of necrotizing fasciitis. Infection often is more extensive than is apparent from external examination. Surgical debridement of infected tissue is extremely important and often requires re-exploration to ensure adequacy of resection.

Consultations:

- Consultation with a surgeon should occur early.
- A consultation with an infectious diseases specialist is mandatory, and a consultation with an intensivist also is required for management of these patients in an intensive care unit.

The goals of pharmacotherapy are to reduce morbidity, prevent complications, and eradicate the infection.

Drug Category: *Antibiotics* -- Antimicrobial therapy must cover all likely pathogens in the context of the clinical setting.

Drug Name	Clindamycin (Cleocin) -- Lincosamide for treatment of serious skin and soft tissue staphylococcal infections. Also effective against aerobic and anaerobic streptococci (except enterococci). As much as 20% of group B streptococci may be resistant. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl tRNA from ribosomes causing RNA-dependent protein synthesis to arrest.
Adult Dose	600 mg IV q8h
Pediatric Dose	25-40 mg/kg/d IV divided tid/qid
Contraindications	Documented hypersensitivity; regional enteritis; ulcerative colitis; antibiotic-associated colitis; hepatic impairment
Interactions	Increases duration of neuromuscular blockage induced by tubocurarine and pancuronium; erythromycin may antagonize effects; antidiarrheals may delay absorption
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis
Drug Name	Aqueous penicillin G (Pfizerpen) -- Interferes with synthesis of cell wall mucopeptide during active multiplication, resulting in bactericidal activity against susceptible microorganisms.
Adult Dose	2-4 million U IV q4h; for streptococcal TSS, not STSS
Pediatric Dose	150,000 U/kg/d IV divided q4h
Contraindications	Documented hypersensitivity
Interactions	Probenecid can increase effects of penicillin; coadministration of tetracyclines can decrease effects of penicillin
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Caution in impaired renal function; traditional drug for the treatment of lung abscess, but its spectrum

	of activity is narrow
Drug Name	Nafcillin (Nafcil, Unipen, Nallpen) -- Initial therapy for suspected penicillin G-resistant staphylococcal infections. Use parenteral therapy initially in severe infections. Due to thrombophlebitis, particularly in elderly patients, administer parenterally only for short term (1-2 d); change to oral route as clinically indicated.
Adult Dose	2 g IV q4h
Pediatric Dose	0-4 kilograms (neonates): 10 mg/kg IM bid 4-40 kilograms: 25 mg/kg IM bid Alternatively, 100-200 mg/kg/d IV/IM in 4-6 divided doses
Contraindications	Documented hypersensitivity
Interactions	Associated with warfarin resistance when administered concurrently; effects may decrease with bacteriostatic action of tetracycline derivatives
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	To optimize therapy, determine causative organisms and susceptibility; >10 d treatment to eliminate infection and prevent sequelae (eg, endocarditis, rheumatic fever); obtain cultures after treatment to confirm that infection is eradicated
Drug Name	Vancomycin (Lymphocin, Vancocin, Vancoled) -- Potent antibiotic directed against gram-positive organisms and active against <i>Enterococcus</i> species. Useful in treatment of patients with septicemia and skin structure infections. Indicated for patients who cannot receive or have failed to respond to penicillins and cephalosporins or who have infections with resistant staphylococci (eg, MRSA). For abdominal penetrating injuries, combine with an agent active against enteric flora and/or anaerobes. Use creatinine clearance to adjust dose in patients with renal impairment.
Adult Dose	1 g IV q12h
Pediatric Dose	40 mg/kg IV divided tid/qid for 7-10 d
Contraindications	Documented hypersensitivity
Interactions	Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; when taken concurrently with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with

	nondepolarizing muscle relaxants
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Caution in renal failure, neutropenia; red man syndrome is caused by too rapid IV infusion (dose administered over a few min) but rarely happens when dose is administered as a 2-h administration or as PO or IP administration; red man syndrome is not an allergic reaction
Drug Name	Oxacillin (Bactocill, Prostaphlin) -- Bactericidal antibiotic that inhibits cell wall synthesis. Used in the treatment of infections caused by penicillinase-producing staphylococci. May be used to initiate therapy when staphylococcal infection is suspected.
Adult Dose	2 g IV q4h
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity
Interactions	Decreases effects of oral contraceptives and tetracycline; when administered concomitantly with disulfiram and probenecid, may increase oxacillin levels; effect of anticoagulants increase when large IV doses of oxacillin are administered
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Caution in renal impairment

FOLLOW-UP

Section 8 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Transfer:

- Most patients who develop TSS are critically ill and should be transferred to an intensive care unit of an institution capable of caring for these patients.

Deterrence/Prevention:

- Patients who recover from TSS are at risk of recurrent episodes of STSS. Consider or recommend preventive therapy (eg, discontinuation of tampon usage, administration of antistaphylococcal antibiotics) before and during each menstrual period for several months.
- Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin.

Complications:

- Severe complications from STSS include the following (Stevens, 1989):

- Prolonged and refractory hypovolemic shock (95%)
- Adult respiratory distress syndrome (55%)
- Acute renal failure (reversible in 70%, irreversible 10%)
- Bacteremia (60%)
- Electrolyte and acid-base imbalance
- Cardiac dysrhythmia
- Disseminated intravascular coagulation with thrombocytopenia
- STSS carries a mortality rate of 3%, and streptococcal TSS has a mortality rate of 30%.
- TSS may recur in patients who are not treated with beta-lactamase-resistant antimicrobial drugs.
- Some patients with streptococcal TSS have respiratory symptoms and develop lobar consolidation and empyema. This condition may need to be distinguished from overwhelming *Streptococcus pneumoniae* sepsis.

Patient Education:

- Patient education about early signs and symptoms, risk factors and avoidance of tampon use may help prevent relapses.
- For excellent patient education resources, visit eMedicine's [Women's Health Center](#). Also, see eMedicine's patient education article [Toxic Shock Syndrome](#).

MISCELLANEOUS

Section 9 of 11

[Author Information](#) [Introduction](#) [Clinical Differentials](#) [Workup](#) [Treatment](#) [Medication](#) [Follow-up](#) [Miscellaneous](#) [Pictures](#) [Bibliography](#)

Medical/Legal Pitfalls:

- Streptococcal TSS emerged as a serious infectious disease in the 20th century.
- Streptococcal TSS is associated with GAS infection and shock and multiorgan failure.
- Rapid progression of what appears to be cellulitis, swelling, formation of vesicles, and bullae is an ominous sign.
- Emergent surgical exploration should be performed to distinguish GAS infection from other causes and debride the necrotic tissues.
- In a female who develops a shock state, a history and/or examination for tampon use should be performed. The STSS should be considered in the differential diagnosis.
- Streptococcal TSS should be considered in any patient who presents from the community in shock. Empirical therapy should be undertaken because culture results may not be available for 24 hours.
- Acute meningococcemia may be confused with streptococcal shock syndrome because of the petechial rash.

BIBLIOGRAPHY

Section 11 of 11

- Anderson JF, Cunha BA: Group A streptococcal necrotizing fasciitis of the psoas muscle. *Heart Lung* 1999 May-Jun; 28(3): 219-21 [[Medline](#)].
- Bachmeyer C, Langman B, Blum L: Fulminant streptococcal necrotizing fasciitis. *Dermatology* 2004; 209(4): 346-7; author reply 347 [[Medline](#)].
- Barry W, Hudgins L, Donta ST: Intravenous immunoglobulin therapy for toxic shock syndrome. *JAMA* 1992 Jun 24; 267(24): 3315-6 [[Medline](#)].
- Bisno AL, Stevens DL: Streptococcal infections of skin and soft tissues. *N Engl J Med* 1996 Jan 25; 334(4): 240-5 [[Medline](#)].
- Bisno AL: Group A streptococcal infections and acute rheumatic fever. *N Engl J Med* 1991 Sep 12; 325(11): 783-93 [[Medline](#)].
- Cone LA, Woodard DR, Schlievert PM: Clinical and bacteriologic observations of a toxic shock-like syndrome due to *Streptococcus pyogenes*. *N Engl J Med* 1987 Jul 16; 317(3): 146-9 [[Medline](#)].
- Cronin L, Cook DJ, Carlet J: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. *Crit Care Med* 1995 Aug; 23(8): 1430-9 [[Medline](#)].
- Davies HD, McGeer A, Schwartz B: Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. *N Engl J Med* 1996 Aug 22; 335(8): 547-54 [[Medline](#)].
- Davis JP, Chesney PJ, Wand PJ: Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. *N Engl J Med* 1980 Dec 18; 303(25): 1429-35 [[Medline](#)].
- Demers B, Simor AE, Vellend H: Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. *Clin Infect Dis* 1993 Jun; 16(6): 792-800; discussion 801-2 [[Medline](#)].
- Ekelund K, Skinhøj P, Madsen J: Reemergence of emm1 and a changed superantigen profile for group A streptococci causing invasive infections: results from a nationwide study. *J Clin Microbiol* 2005 Apr; 43(4): 1789-96 [[Medline](#)].
- Eriksson BK, Andersson J, Holm SE: Epidemiological and clinical aspects of invasive group A streptococcal infections and the streptococcal toxic shock syndrome. *Clin Infect Dis* 1998 Dec; 27(6): 1428-36 [[Medline](#)].
- Hribalova V: *Streptococcus pyogenes* and the toxic shock syndrome. *Ann Intern Med* 1988 May; 108(5): 772 [[Medline](#)].
- Issa NC, Thompson RL: Staphylococcal toxic shock syndrome. Suspicion and prevention are keys to control. *Postgrad Med* 2001 Oct; 110(4): 55-6, 59-62 [[Medline](#)].
- Kaul R, McGeer A, Low DE: Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. *Am J Med* 1997 Jul; 103(1): 18-24 [[Medline](#)].
- Kaul R, McGeer A, Norrby-Teglund A: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. *Clin Infect Dis* 1999 Apr; 28(4): 800-7 [[Medline](#)].
- Lee YT, Chou TD, Peng MY: Rapidly progressive necrotizing fasciitis caused by *Staphylococcus aureus*. *J Microbiol Immunol Infect* 2005 Oct; 38(5): 361-4 [[Medline](#)].
- Lina G, Vandenesch F, Etienne J: [Staphylococcal and streptococcal pediatric toxic syndrome from 1998 to 2000. Data from the National Center for Staphylococcal Toxemia]. *Arch Pediatr* 2001 Sep; 8 Suppl 4: 769s-775s [[Medline](#)].
- Martin PR, Hoiby EA: Streptococcal serogroup A epidemic in Norway 1987-1988. *Scand J Infect Dis* 1990; 22(4): 421-9 [[Medline](#)].
- Mascini EM, Jansze M, Schouls LM: Penicillin and clindamycin differentially inhibit the production of pyrogenic exotoxins A and B by group A streptococci. *Int J Antimicrob Agents* 2001 Oct; 18(4): 395-8 [[Medline](#)].
- Mulla ZD: Treatment options in the management of necrotising fasciitis caused by Group A

- Streptococcus. *Expert Opin Pharmacother* 2004 Aug; 5(8): 1695-700[[Medline](#)].
- Norrby-Teglund A, Newton D, Kotb M: Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). *Infect Immun* 1994 Dec; 62(12): 5227-33[[Medline](#)].
 - Norrby-Teglund A, Muller MP, Mcgeer A: Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. *Scand J Infect Dis* 2005; 37(3): 166-72[[Medline](#)].
 - RodrÁguez A, Rello J, Neira J: Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. *Shock* 2005 Apr; 23(4): 298-304[[Medline](#)].
 - Schumann C, Triantafilou K, Kamenz J: Septic shock caused by *Streptococcus pneumoniae* in a post-splenectomy patient successfully treated with recombinant human activated protein C. *Scand J Infect Dis* 2006; 38(2): 139-42[[Medline](#)].
 - Schwartz B, Facklam RR, Breiman RF: Changing epidemiology of group A streptococcal infection in the USA. *Lancet* 1990 Nov 10; 336(8724): 1167-71[[Medline](#)].
 - Shands KN, Schmid GP, Dan BB: Toxic-shock syndrome in menstruating women: association with tampon use and *Staphylococcus aureus* and clinical features in 52 cases. *N Engl J Med* 1980 Dec 18; 303(25): 1436-42[[Medline](#)].
 - Sims KD, Barton TD: Group B streptococcal toxic shock syndrome in an asplenic patient: case report and literature review. *Eur J Clin Microbiol Infect Dis* 2006 Mar; 25(3): 208-10[[Medline](#)].
 - Stegmayr B, Bjorck S, Holm S: Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. *Scand J Infect Dis* 1992; 24(5): 589-97[[Medline](#)].
 - Stevens DL, Bryant AE, Hackett SP: Antibiotic effects on bacterial viability, toxin production, and host response. *Clin Infect Dis* 1995 Jun; 20 Suppl 2: S154-7[[Medline](#)].
 - Stevens DL, Bryant AE, Hackett SP: Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure. *J Infect Dis* 1996 Mar; 173(3): 619-26[[Medline](#)].
 - Stevens DL, Tanner MH, Winship J: Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. *N Engl J Med* 1989 Jul 6; 321(1): 1-7[[Medline](#)].
 - Stevens DL: Invasive group A streptococcus infections. *Clin Infect Dis* 1992 Jan; 14(1): 2-11[[Medline](#)].
 - Stevens DL: The flesh-eating bacterium: what's next? *J Infect Dis* 1999 Mar; 179 Suppl 2: S366-74[[Medline](#)].
 - Tang J, Wang C, Feng Y: Streptococcal Toxic Shock Syndrome Caused by *Streptococcus suis* Serotype 2. *PLoS Med* 2006 Apr 11; 3(5): e151[[Medline](#)].
 - Thomas JC, Carr SJ, Fujioka K: Community-acquired group A streptococcal deaths in Los Angeles County. *J Infect Dis* 1989 Dec; 160(6): 1086-7[[Medline](#)].
 - Todd J, Fishaut M, Kapral F: Toxic-shock syndrome associated with phage-group-I *Staphylococci*. *Lancet* 1978 Nov 25; 2(8100): 1116-8[[Medline](#)].
 - Weiss KA, Laverdiere M: Group A *Streptococcus* invasive infections: a review. *Can J Surg* 1997 Feb; 40(1): 18-25[[Medline](#)].
 - Wheeler MC, Roe MH, Kaplan EL: Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. *JAMA* 1991 Jul 24-31; 266(4): 533-7[[Medline](#)].
 - Working Group on Severe Streptococcal Infections: Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections. *JAMA* 1993 Jan 20; 269(3): 390-1[[Medline](#)].
 - Yan S, Mendelman PM, Stevens DL: The in vitro antibacterial activity of ceftriaxone against *Streptococcus pyogenes* is unrelated to penicillin-binding protein 4. *FEMS Microbiol Lett* 1993 Jul 1; 110(3): 313-7[[Medline](#)].